You are here


A search here on HQP1351 gives no result. Is this a TKI  we know about under a different title?

FDA grants orphan drug designation to HQP1351 for chronic myeloid leukemia



It seems it is a newly developed 3rd Gen TKI by Ascentage Pharma...

HQP1351 is a novel, orally active, potent third-generation BCR-ABL inhibitor designed to effectively target BCR-ABL mutants, including T315I, and it is being developed for the treatment of patients with CML resistant to first- and second-generation TKIs. HQP1351 is the first China-developed third-generation BCR-ABL inhibitor targeting drug-resistant CML. The drug candidate is currently being evaluated in pivotal Phase II studies in China, and Ascentage Pharma plans to submit an NDA for HQP1351 this year. In July 2019, HQP1351 was cleared by FDA to enter a Phase Ib study. Data from the Phase I clinical study of HQP1351 were selected for oral presentations at the American Society of Hematology (ASH) Annual Meetings two years in a row and was nominated as "Best of ASH" research in 2019. Early data from studies of HQP1351 have demonstrated promising efficacy as well as favorable safety and tolerability profiles.

Hello Sandy. Thank you, I was hoping that that would be the answer. That is another third line TKI in our armoury.